bapineuzumab
E559467
Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
Statements (37)
| Predicate | Object |
|---|---|
| instanceOf |
Alzheimer’s disease therapy candidate
ⓘ
investigational drug ⓘ monoclonal antibody ⓘ |
| actsOnPathway | amyloid cascade in Alzheimer’s disease ⓘ |
| administeredTo | patients with Alzheimer’s disease ⓘ |
| adverseEffect |
amyloid-related imaging abnormalities
ⓘ
microhemorrhage ⓘ vasogenic edema ⓘ |
| belongsToTherapeuticArea |
neurodegenerative diseases
ⓘ
neurology ⓘ |
| biologicType | IgG monoclonal antibody ⓘ |
| clinicalTrialPhase |
Phase II
ⓘ
Phase III ⓘ |
| developedFor | Alzheimer’s disease NERFINISHED ⓘ |
| developmentGoal | disease-modifying treatment for Alzheimer’s disease ⓘ |
| developmentStatus | clinical development discontinued ⓘ |
| drugClass | anti-amyloid monoclonal antibody ⓘ |
| hasEpitope | N-terminus of amyloid beta ⓘ |
| hasMolecularTarget | extracellular amyloid beta plaques ⓘ |
| indicationTestedIn |
mild Alzheimer’s disease
ⓘ
moderate Alzheimer’s disease ⓘ |
| intendedEffect |
reduce amyloid plaque burden
ⓘ
slow cognitive decline in Alzheimer’s disease ⓘ |
| isHumanizedFrom | mouse monoclonal antibody ⓘ |
| isInvestigatedIn | clinical trials for Alzheimer’s disease ⓘ |
| isNotApprovedFor | treatment of Alzheimer’s disease ⓘ |
| isParenteralDrug | true ⓘ |
| mechanismOfAction |
binds beta-amyloid plaques in the brain
ⓘ
promotes clearance of amyloid beta ⓘ |
| reasonForDiscontinuation | lack of efficacy in Phase III trials ⓘ |
| routeOfAdministration | intravenous ⓘ |
| target |
amyloid beta peptide
ⓘ
beta-amyloid NERFINISHED ⓘ |
| therapeuticApproach | passive immunization against amyloid beta ⓘ |
| therapyType | immunotherapy ⓘ |
| trialOutcome |
did not meet primary cognitive endpoints in Phase III
ⓘ
showed limited clinical benefit ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.